Q32 Bio Inc. (QTTB)
Automate Your Wheel Strategy on QTTB
With Tiblio's Option Bot, you can configure your own wheel strategy including QTTB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol QTTB
- Rev/Share 0.0
- Book/Share 0.4659
- PB 3.3269
- Debt/Equity 3.3306
- CurrentRatio 4.9728
- ROIC -0.5739
- MktCap 18906280.0
- FreeCF/Share -5.5654
- PFCF -0.2789
- PE -0.3955
- Debt/Assets 0.2047
- DivYield 0
- ROE -1.797
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | QTTB | Piper Sandler | Overweight | Neutral | $20 | $4 | Feb. 11, 2025 |
| Downgrade | QTTB | BMO Capital Markets | Outperform | Market Perform | $22 | $3 | Feb. 11, 2025 |
| Downgrade | QTTB | Leerink Partners | Outperform | Market Perform | $68 | $9 | Dec. 11, 2024 |
| Downgrade | QTTB | Raymond James | Strong Buy | Outperform | $90 | $22 | Dec. 11, 2024 |
| Downgrade | QTTB | Wells Fargo | Overweight | Equal Weight | $95 | $16 | Dec. 11, 2024 |
| Downgrade | QTTB | Guggenheim | Buy | Neutral | -- | -- | Dec. 11, 2024 |
| Initiation | QTTB | BMO Capital Markets | -- | Outperform | -- | $64 | Dec. 6, 2024 |
| Initiation | QTTB | Wells Fargo | -- | Overweight | -- | $95 | Sept. 11, 2024 |
News
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
-- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 -- -- First patient dosed in SIGNAL-AA Part A open-label extension (OLE) -- -- Fast Track designation (FTD) granted to bempikibart for the treatment of alopecia areata (AA); SIGNAL-AA Part A results presented as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting -- -- Cash and cash equivalents of $65.5 million as of March 31, 2025 expected to provide financial runway into 2H'26 -- WALTHAM, Mass. , May 8, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 …
Read More
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
WALTHAM, Mass. , April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that the United States Food and Drug Administration ("FDA") has granted Fast Track designation (FTD) to Q32 Bio's bempikibart (ADX-914) for the treatment of AA.
Read More
All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
Published: February 28, 2025 by: PRNewsWire
Sentiment: Neutral
-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) -- WALTHAM, Mass. , Feb. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) will be presented in a late-breaking oral session at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking …
Read More
Q32 Bio to Participate in Upcoming March Investor Conferences
Published: February 26, 2025 by: PRNewsWire
Sentiment: Neutral
WALTHAM, Mass. , Feb. 26, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in two upcoming investor conferences in March: TD Cowen 45th Annual Health Care Conference Date: Wednesday, March 5, 2025 Presentation Time: 11:50 a.m.
Read More
About Q32 Bio Inc. (QTTB)
- IPO Date 2018-03-28
- Website https://www.q32bio.com
- Industry Biotechnology
- CEO Ms. Jodie Pope Morrison
- Employees 28